ImmunityBio in Focus as EU Decision Nears, Shares Hover Above Key Level

ImmunityBio US45256X1037

ImmunityBio finished the first trading day of 2026 at $2.02, representing a 2.02% gain. The stock sits just above the $2.00 psychological threshold as investors await a ruling from the European Commission. Will an EU approval spark the anticipated push higher in the shares? The following points lay out the relevant facts.

• On December 12, 2025, the EMA’s CHMP issued a positive recommendation for conditional approval of ANKTIVA (nogapendekin alfa inbakicept) in combination with BCG for adults with BCG-unresponsive NMIBC CIS.
• This recommendation remains the principal fundamental driver. Typically, a formal EC decision follows a positive CHMP vote within roughly 67 days.
• The market has priced in a high likelihood of approval, yet short-interest rose about 23% in December, indicating prevailing skepticism among some market participants.
• At year-end, a financial publication named the stock a 2026 turnaround candidate, underscoring the EU decision as a key growth driver.

Financials, market outlook and potential impact

• ImmunityBio reported for November, on the third quarter, an EPS of -$0.07 per share versus an expected -$0.10, with revenue of $32.06 million. This suggests early commercial progress in the United States.
• An EU approval would accelerate commercial scaling and could trigger contractually defined milestone payments.

Technical viewpoint:
- Maintaining the $2.00 level is important for near-term direction.
- A move below this mark could prompt a retest of the 52-week low near $1.83.
- Conversely, a sustained break above $2.15 on rising volume would confirm a recovery in momentum.

Timeline and broker perspective

Market guidance points to the European Commission’s decision window as late February to early March 2026. A formal approval would represent a meaningful catalyst, clarifying Europe’s revenue potential and scaling trajectory. Some research desks, including Jefferies, continue to rate the shares as a Buy with price targets positioned above the current level.